Anavex Life Sciences (AVXL)
(Real Time Quote from BATS)
$6.47 USD
-0.11 (-1.67%)
Updated Aug 2, 2024 03:00 PM ET
3-Hold of 5 3
C Value C Growth A Momentum C VGM
Brokerage Reports
0 items in cart
Anavex Life Sciences Corp. [AVXL]
Reports for Purchase
Showing records 141 - 157 ( 157 total )
Company: Anavex Life Sciences Corp.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Anavex Life Sciences Corp.
Industry: Medical - Biomedical and Genetics
AAIC Presentations Show Genetic Marker Data And Trial Design
Provider: Roth Capital Partners, Inc.
Analyst: LEBOYER R
Company: Anavex Life Sciences Corp.
Industry: Medical - Biomedical and Genetics
An Update From the Alzheimer?s Association International Conference (AAIC)
Provider: H.C. Wainwright & Co., Inc.
Analyst: KOLBERT J
Company: Anavex Life Sciences Corp.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Anavex Life Sciences Corp.
Industry: Medical - Biomedical and Genetics
Anavex2-73 Gets the Go for Parkinson''s Disease With Dementia in Spain
Provider: H.C. Wainwright & Co., Inc.
Analyst: KOLBERT J
Company: Anavex Life Sciences Corp.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Anavex Life Sciences Corp.
Industry: Medical - Biomedical and Genetics
Moving Forward in Alzheimer''s Disease Down Under
Provider: H.C. Wainwright & Co., Inc.
Analyst: KOLBERT J
Company: Anavex Life Sciences Corp.
Industry: Medical - Biomedical and Genetics
Lilly''s BACE Inhibitor Trial Fails; the Time Seems Right to Look at an Alternative Approach to AD
Provider: H.C. Wainwright & Co., Inc.
Analyst: KOLBERT J
Company: Anavex Life Sciences Corp.
Industry: Medical - Biomedical and Genetics
ANAVEX2-73 Represents a New Approach in CNS Disorders; Initiating Coverage With a Buy Rating and a $10 Price Target
Provider: H.C. Wainwright & Co., Inc.
Analyst: KOLBERT J
Company: Anavex Life Sciences Corp.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Anavex Life Sciences Corp.
Industry: Medical - Biomedical and Genetics
Reports 2Q18 and Makes Expected Clinical Progress
Provider: Roth Capital Partners, Inc.
Analyst: LEBOYER R
Company: Anavex Life Sciences Corp.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Anavex Life Sciences Corp.
Industry: Medical - Biomedical and Genetics
Parkinson''s Disease Trial Expands The Pipeline For ANAVEX 2-73
Provider: Roth Capital Partners, Inc.
Analyst: LEBOYER R
Company: Anavex Life Sciences Corp.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Anavex Life Sciences Corp.
Industry: Medical - Biomedical and Genetics
Initiating Coverage on Companies with Novel Approaches to Alzheimer''s Disease
Provider: Roth Capital Partners, Inc.
Company: Anavex Life Sciences Corp.
Industry: Medical - Biomedical and Genetics
Initiating Coverage With a $6 Price Target
Provider: Roth Capital Partners, Inc.
Company: Anavex Life Sciences Corp.
Industry: Medical - Biomedical and Genetics
We initiate coverage with a price target of $1.33 per share
Provider: SEETHRUEQUITY, LLC
Analyst: TANDON A